Vericel (VCEL) Competitors $32.18 -1.35 (-4.03%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$32.18 0.00 (0.00%) As of 09/12/2025 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VCEL vs. RYTM, LEGN, ABVX, RNA, CYTK, AXSM, NUVL, TGTX, MRUS, and CRSPShould you be buying Vericel stock or one of its competitors? The main competitors of Vericel include Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Abivax (ABVX), Avidity Biosciences (RNA), Cytokinetics (CYTK), Axsome Therapeutics (AXSM), Nuvalent (NUVL), TG Therapeutics (TGTX), Merus (MRUS), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry. Vericel vs. Its Competitors Rhythm Pharmaceuticals Legend Biotech Abivax Avidity Biosciences Cytokinetics Axsome Therapeutics Nuvalent TG Therapeutics Merus CRISPR Therapeutics Rhythm Pharmaceuticals (NASDAQ:RYTM) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership. Is RYTM or VCEL more profitable? Vericel has a net margin of 2.85% compared to Rhythm Pharmaceuticals' net margin of -117.13%. Vericel's return on equity of 2.47% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-117.13% -1,831.43% -48.33% Vericel 2.85%2.47%1.69% Do analysts rate RYTM or VCEL? Rhythm Pharmaceuticals currently has a consensus target price of $101.57, indicating a potential upside of 5.56%. Vericel has a consensus target price of $60.40, indicating a potential upside of 87.69%. Given Vericel's higher probable upside, analysts clearly believe Vericel is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07Vericel 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer RYTM or VCEL? In the previous week, Rhythm Pharmaceuticals had 1 more articles in the media than Vericel. MarketBeat recorded 8 mentions for Rhythm Pharmaceuticals and 7 mentions for Vericel. Rhythm Pharmaceuticals' average media sentiment score of 1.69 beat Vericel's score of 0.88 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Vericel 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has higher valuation & earnings, RYTM or VCEL? Vericel has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$130.13M49.11-$260.60M-$3.01-31.97Vericel$249.12M6.52$10.36M$0.12268.17 Which has more risk and volatility, RYTM or VCEL? Rhythm Pharmaceuticals has a beta of 2.23, suggesting that its stock price is 123% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. SummaryVericel beats Rhythm Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Vericel News Delivered to You Automatically Sign up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCEL vs. The Competition Export to ExcelMetricVericelMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.62B$3.15B$5.78B$10.18BDividend YieldN/A2.32%5.73%4.60%P/E Ratio268.1921.5775.5726.02Price / Sales6.52254.90461.9291.11Price / Cash102.9844.4425.8129.91Price / Book5.449.6112.526.25Net Income$10.36M-$53.29M$3.29B$270.76M7 Day Performance-3.13%0.57%0.78%2.54%1 Month Performance-11.30%4.56%4.56%5.73%1 Year Performance-29.85%10.44%66.82%25.85% Vericel Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCELVericel3.0349 of 5 stars$32.18-4.0%$60.40+87.7%-29.8%$1.62B$249.12M268.19300RYTMRhythm Pharmaceuticals3.2576 of 5 stars$99.77-2.3%$101.57+1.8%+93.9%$6.78B$130.13M-33.15140Positive NewsLEGNLegend Biotech3.1863 of 5 stars$34.62-4.0%$74.22+114.4%-34.2%$6.66B$627.24M0.002,609Positive NewsABVXAbivax2.5649 of 5 stars$90.00+2.2%$92.33+2.6%+616.8%$6.65BN/A0.0061News CoveragePositive NewsEarnings ReportAnalyst ForecastShort Interest ↑RNAAvidity Biosciences2.1004 of 5 stars$48.05-4.6%$67.00+39.4%+7.3%$6.48B$10.90M-13.50190Trending NewsAnalyst ForecastGap UpCYTKCytokinetics4.3865 of 5 stars$52.09-1.7%$75.38+44.7%-8.5%$6.34B$18.47M-10.21250Positive NewsAXSMAxsome Therapeutics4.9151 of 5 stars$129.29+3.3%$177.86+37.6%+26.4%$6.25B$385.69M-25.50380Positive NewsNUVLNuvalent2.9934 of 5 stars$79.83-1.3%$120.91+51.5%-8.0%$5.83BN/A-16.2940Insider TradeTGTXTG Therapeutics4.2988 of 5 stars$32.38+0.5%$46.25+42.8%+35.5%$5.11B$329M87.51290Positive NewsInsider TradeMRUSMerus2.878 of 5 stars$67.19-0.4%$88.75+32.1%+38.8%$5.10B$36.13M-12.2237Positive NewsCRSPCRISPR Therapeutics3.284 of 5 stars$54.10-1.4%$71.60+32.3%+15.0%$4.99B$37.31M-9.96460Positive News Related Companies and Tools Related Companies RYTM Competitors LEGN Competitors ABVX Competitors RNA Competitors CYTK Competitors AXSM Competitors NUVL Competitors TGTX Competitors MRUS Competitors CRSP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VCEL) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Vericel With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
